GNH USA

Europe — EMA

Irinotecan Hydrochloride Eugia (Uk) (Irinotecan Hydrochloride Trihydrate)

GNH USA supplies Irinotecan Hydrochloride Eugia (Irinotecan), a topoisomerase I inhibitor for metastatic colorectal cancer and colorectal cancer.

Irinotecan Hydrochloride Trihydrate

Request sourcing

1
Pack/s

What is Irinotecan Hydrochloride Trihydrate?

Irinotecan Hydrochloride, the active ingredient in Irinotecan Hydrochloride Eugia (Uk), is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer and other colorectal cancers in adult patients.

GNH USA supplies Irinotecan Hydrochloride Eugia (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

What is Irinotecan Hydrochloride Trihydrate used for?

Irinotecan Hydrochloride is used in oncology to target colorectal tumor pathways. It is indicated for the following conditions: - Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy. - Colorectal cancer (advanced): provides disease control in patients with unresectable disease. - Colorectal cancer (adjuvant): used post‑surgery to reduce recurrence risk.

What are the side effects of Irinotecan Hydrochloride Trihydrate?

Irinotecan Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: often severe and may require supportive care. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: may be managed with antiemetics. - Fatigue: generalized tiredness during treatment. - Alopecia: hair loss in some patients. - Abdominal cramping: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe diarrhea leading to dehydration. - Intestinal perforation or obstruction. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe allergic reactions: rash, bronchospasm, or anaphylaxis. - Bone marrow suppression resulting in anemia or thrombocytopenia.

What precautions apply to Irinotecan Hydrochloride Trihydrate?

Before initiating Irinotecan Hydrochloride therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: baseline and periodic LFTs are recommended. - Adjust dose in hepatic impairment: use caution and consider dose reduction. - Caution with prior bowel disease: increased risk of severe diarrhea. - Avoid concurrent strong CYP3A4 inhibitors: may raise drug exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

What does Irinotecan Hydrochloride Trihydrate interact with?

Irinotecan Hydrochloride interacts with several medications that can alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase toxicity risk. - UGT1A1 inhibitors (e.g., atazanavir): raise SN‑38 levels and toxicity. - Concurrent myelosuppressive agents: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may affect metabolism. - Warfarin: monitor INR for altered anticoagulation. - Nephrotoxic drugs: watch renal function and adjust dosing if needed.

Frequently asked questions

What is Irinotecan Hydrochloride used for?+
Irinotecan Hydrochloride is an anticancer agent used primarily in the treatment of metastatic colorectal cancer and advanced colorectal tumors. It is administered intravenously as part of combination chemotherapy regimens to improve survival and control disease progression.
How does Irinotecan Hydrochloride work?+
The drug is a pro‑drug that is converted inside cancer cells to SN‑38, which inhibits topoisomerase I. This enzyme normally relieves DNA supercoiling during replication; its inhibition leads to accumulation of DNA breaks, triggering cell death in rapidly dividing tumor cells.
What is the usual dose of Irinotecan Hydrochloride?+
The dosing regimen for Irinotecan Hydrochloride is determined by the prescribing oncologist based on the patient’s weight, disease stage, and treatment protocol. Specific dose calculations and schedules are individualized and should follow established clinical guidelines.
Is Irinotecan Hydrochloride safe during pregnancy or breastfeeding?+
Safety data for Irinotecan Hydrochloride in pregnancy and lactation are limited. It is generally contraindicated in pregnant or nursing women because of potential fetal toxicity and drug excretion in breast milk. Consultation with a specialist is essential before use.
How do I order Irinotecan Hydrochloride from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.
How does Irinotecan Hydrochloride compare with other colorectal cancer drugs?+
Irinotecan belongs to the topoisomerase I inhibitor class, offering a distinct mechanism from fluoropyrimidines or oxaliplatin. It is often combined with these agents to enhance efficacy. Compared with alternatives, Irinotecan provides a different toxicity profile, notably higher rates of diarrhea and neutropenia, which may influence regimen selection.
What are the storage and handling requirements for Irinotecan Hydrochloride?+
The injectable formulation should be stored refrigerated at 2‑8 °C, protected from light, and never frozen. Prior to administration, the solution must be inspected for particulate matter and used within the time frame specified by the manufacturer’s labeling.
How is Irinotecan Hydrochloride administered?+
Irinotecan Hydrochloride is given by intravenous infusion, typically over 30‑90 minutes depending on the protocol. Administration is performed in a clinical setting by qualified healthcare professionals, with monitoring for infusion‑related reactions and supportive care as needed.
What are the most serious risks associated with Irinotecan Hydrochloride?+
The most serious adverse events include severe neutropenia leading to infection, febrile neutropenia, life‑threatening diarrhea, intestinal perforation, and hepatic toxicity. Prompt recognition and management of these conditions are critical to patient safety.
Who should not use Irinotecan Hydrochloride?+
Patients with known hypersensitivity to Irinotecan or its excipients, those with severe hepatic impairment, and individuals with active uncontrolled infections should avoid the drug. Additionally, patients with a history of severe bowel disease may be at increased risk for complications.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Irinotecan Hydrochloride Trihydrate
Route
Intravenous Use
Manufacturer
Eugia (Uk) Ltd
Origin
EU

Related products

Campto

Campto

Irinotecan Hydrochloride Trihydrate

Pfizer S.A.
EU
Campto

Campto

Irinotecan Hydrochloride Trihydrate

Pfizer Holding France
EU
Campto

Campto

Irinotecan Hydrochloride Trihydrate

Pfizer Hellas A.E.
EU
Campto

Campto

Irinotecan Hydrochloride Trihydrate

Pfizer Healthcare Ireland Unlimited Company
EU